Brolucizumab 12- and 16-week fixed dosing potential in neovascular AMD: a post-hoc evaluation of data from the HAWK and HARRIER trials

Conclusions: This analysis demonstrates the potential durability of action and effectiveness of brolucizumab.

Source: Ophthalmologica - March 28, 2022 Category: Opthalmology Source Type: research